keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer stage D2.5 trials

keyword
https://www.readbyqxmd.com/read/23622710/a-comparative-dosimetric-analysis-of-virtual-stereotactic-body-radiotherapy-to-high-dose-rate-monotherapy-for-intermediate-risk-prostate-cancer
#1
COMPARATIVE STUDY
Daniel E Spratt, Lawrence M Scala, Michael Folkert, Laszlo Voros, Gil'ad N Cohen, Laura Happersett, Evangelia Katsoulakis, Michael J Zelefsky, Marisa A Kollmeier, Yoshiya Yamada
PURPOSE: Stereotactic body radiotherapy (SBRT) is being used with increasing frequency as definitive treatment of early stage prostate cancer. Much of the justification for its adoption was derived from earlier clinical results using high-dose-rate (HDR) brachytherapy. We determine whether HDR's dosimetry can be achieved by virtual SBRT. METHODS AND MATERIALS: Patients with intermediate-risk prostate cancer on a prospective trial evaluating the efficacy of HDR monotherapy treated to dose of 9...
September 2013: Brachytherapy
https://www.readbyqxmd.com/read/22735362/renal-effects-of-high-dose-celecoxib-in-elderly-men-with-stage-d2-prostate-carcinoma
#2
Payam Benson, Michael Yudd, Derrick Sims, Victor Chang, Shanthi Srinivas, Basil Kasimis
AIM: To prospectively study the clinical renal effects of daily high-dose celecoxib, a COX-2 inhibitor, in a cohort of elderly sick men (mean age 74.5 years) with advanced prostate cancer. MATERIAL AND METHOD: 44 men with advanced hormoneresistant prostate cancer participated in oncologic Phase II trials. All received celecoxib 400 mg bid for a median 6 months. Monthly laboratory measurement and blood pressure were monitored, and all cases of acute kidney injury (creatinine > 50% above baseline) and hyperkalemia (potassium > 5...
November 2012: Clinical Nephrology
https://www.readbyqxmd.com/read/16230148/is-combined-androgen-blockade-with-bicalutamide-cost-effective-compared-with-combined-androgen-blockade-with-flutamide
#3
COMPARATIVE STUDY
Scott Ramsey, David Veenstra, Lauren Clarke, Sanjay Gandhi, Mark Hirsch, David Penson
OBJECTIVES: To determine the cost-effectiveness of combined androgen blockade (CAB) with bicalutamide versus CAB with flutamide in men with Stage D2 prostate cancer. Both bicalutamide and flutamide are commonly used in CAB for prostate cancer. Although the cost of bicalutamide is more than that of flutamide, it is important that the efficacy, quality of life, and side effects are also considered when determining whether CAB with bicalutamide is a cost-effective option. METHODS: A decision model was created to compare treatment strategies...
October 2005: Urology
https://www.readbyqxmd.com/read/16037707/prospective-study-of-estramustine-phosphate-for-hormone-refractory-prostate-cancer-patients-following-androgen-deprivation-therapy
#4
MULTICENTER STUDY
Daisaku Hirano, Sadatsugu Minei, Yuichi Kishimoto, Kenya Yamaguchi, Takahiko Hachiya, Toshio Yoshida, Tetsuo Yoshikawa, Makoto Endoh, Yataroh Yamanaka, Tadao Yamamoto, Yasuo Satoh, Hajime Ishida, Kiyoki Okada, Yukie Takimoto
INTRODUCTION: Estramustine phosphate (EMP) in combination with other cytotoxic agents has been widely used in clinical trials as an anti-tumor agent for the treatment of hormone-refractory prostate cancer (HRPC). However, few prospective studies have considered the efficacy of EMP monotherapy for HRPC patients following androgen-deprivation therapy (ADT), given the availability of methods to measure prostate-specific antigen (PSA) levels in the serum. We therefore initiated a prospective study to determine whether EMP is efficient for HRPC following ADT using changes in PSA levels as the major endpoint...
2005: Urologia Internationalis
https://www.readbyqxmd.com/read/11502463/the-role-of-diethylstilbestrol-in-the-treatment-of-prostate-cancer
#5
REVIEW
S B Malkowicz
OBJECTIVES: Diethylstilbestrol administration was a classic form of androgen deprivation therapy (ADT) that gradually fell out of favor because of its cardiovascular toxicity, economic disinterest on the part of manufacturers, and the emergence of novel therapeutic agents with a superior safety profile. The cost of contemporary agents and the efficacy of diethylstilbestrol (DES) have perpetuated the evaluation of this agent, especially in the circumstance of early hormone-refractory (clinical stage D2...
August 2001: Urology
https://www.readbyqxmd.com/read/11275705/octreotide-in-the-management-of-hormone-refractory-prostate-cancer
#6
REVIEW
I G Vainas
Patients with advanced or metastatic prostate cancer (PC), a partially hormone-resistant disease, will require some form of hormonal manipulations or some new therapeutic modalities. Octreotide, as somatostatin (SST) analogs, has been found to inhibit the growth of experimental PCs via several mechanisms, as indirect antihormonal and direct antimitogenic actions, mainly due to inhibition of SST receptor subtypes (SSTR-1-5). Sporadic clinical trials with octreotide (alone or with a complete antiandrogen blockade) treatment of patients with advanced stage D2 PC demonstrated promising results...
2001: Chemotherapy
https://www.readbyqxmd.com/read/11036467/survival-of-patients-who-had-salvage-castration-after-failure-on-bicalutamide-monotherapy-for-stage-d2-prostate-cancer
#7
B Kasimis, G Wilding, W Kreis, M Feuerman, V Chang, S Hwang, H Steafather, J Cogswell, C Rae, M Blumenfrucht
Patients with hormone-naive stage D2 prostate cancer often benefit from castration. This treatment, however, frequently produces many unacceptable physical and psychological side effects, especially in younger and sexually active patients. Bicalutamide is an oral antiandrogen with excellent tolerance and preservation of sexual function. Three institutions participated in phase II and III trials of bicalutamide monotherapy (50 mg daily) as primary therapy in hormone-naive patients with stage D2 prostate cancer...
2000: Cancer Investigation
https://www.readbyqxmd.com/read/10592501/a-phase-ii-trial-of-gallium-nitrate-in-patients-with-androgen-metastatic-prostate-cancer
#8
A M Senderowicz, R Reid, D Headlee, T Abornathy, J Horti, R M Lush, E Reed, W D Figg, E A Sausville
INTRODUCTION: Due to in vitro data suggesting antitumor activity with gallium nitrate, we sought to evaluate the safety and activity in patients with androgen-independent prostate cancer. METHOD: Patients were eligible for this study if they had an ECOG performance status of < or = 2, stage D2 metastatic prostate cancer that was progressing following combined androgen ablation (medical or surgical castration plus antiandrogen) and had failed antiandrogen withdrawal...
1999: Urologia Internationalis
https://www.readbyqxmd.com/read/10499600/a-pharmacokinetically-guided-phase-ii-study-of-carboxyamido-triazole-in-androgen-independent-prostate-cancer
#9
K S Bauer, W D Figg, J M Hamilton, E C Jones, A Premkumar, S M Steinberg, V Dyer, W M Linehan, J M Pluda, E Reed
We conducted a Phase II clinical trial of the antiproliferative, antimetastatic, and antiangiogenic agent carboxyamido-triazole (CAI), using pharmacokinetic assessment to guide drug dosing. Fifteen patients who had stage D2 androgen-independent prostate cancer with soft tissue metastases were enrolled. Because CAI previously had been shown to decrease prostate-specific antigen secretion in vitro, this marker was not used to assess disease status. The dose of CAI used in this study was calculated so that plasma steady-state maximum concentrations between 2...
September 1999: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/9671875/comparison-of-goserelin-and-leuprolide-in-combined-androgen-blockade-therapy
#10
RANDOMIZED CONTROLLED TRIAL
M F Sarosdy, P F Schellhammer, R Sharifi, N L Block, M S Soloway, P M Venner, A L Patterson, N J Vogelzang, G W Chodak, E A Klein, J J Schellenger, G J Kolvenbag
OBJECTIVES: To perform exploratory analyses of data from a controlled trial that assessed the efficacy and tolerability of two antiandrogens, bicalutamide and flutamide, each combined with monthly depot preparations of leuprolide or goserelin, in patients with Stage D2 prostate cancer. One analysis compared goserelin plus antiandrogen therapy with leuprolide plus antiandrogen therapy; a second analysis compared the four combined androgen blockade (CAB) regimens. METHODS: This was a randomized, multicenter trial, open-label for luteinizing hormone releasing hormone analogue (LHRH-A) therapy, double-blind for antiandrogen therapy, with a two-by-two factorial design...
July 1998: Urology
https://www.readbyqxmd.com/read/9301693/clinical-benefits-of-bicalutamide-compared-with-flutamide-in-combined-androgen-blockade-for-patients-with-advanced-prostatic-carcinoma-final-report-of-a-double-blind-randomized-multicenter-trial-casodex-combination-study-group
#11
RANDOMIZED CONTROLLED TRIAL
P F Schellhammer, R Sharifi, N L Block, M S Soloway, P M Venner, A L Patterson, M F Sarosdy, N J Vogelzang, J J Schellenger, G J Kolvenbag
OBJECTIVES: To compare the efficacy and tolerability of bicalutamide and flutamide, each combined with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with metastatic (Stage D2) prostate cancer. METHODS: This was a randomized, double-blind (for antiandrogen therapy), multicenter study with a two-by-two factorial design. Eight hundred thirteen patients were allocated 1:1 to bicalutamide (50 mg once daily) and flutamide (250 mg three times daily) and 2:1 to goserelin acetate (3...
September 1997: Urology
https://www.readbyqxmd.com/read/9193342/phase-ii-trial-of-suramin-leuprolide-and-flutamide-in-previously-untreated-metastatic-prostate-cancer
#12
N A Dawson, W D Figg, M R Cooper, O Sartor, R C Bergan, A M Senderowicz, S M Steinberg, A Tompkins, B Weinberger, E A Sausville, E Reed, C E Myers
PURPOSE: To assess the efficacy and toxicity of suramin, hydrocortisone, leuprolide, and flutamide in previously untreated metastatic prostate cancer. PATIENTS AND METHODS: Patients with stage D2 and poor-prognosis stage D1 prostate cancer were given suramin on a pharmacokinetically derived dosing schedule to maintain suramin concentrations between 175 and 300 micrograms/mL. Additionally, all patients received flutamide 250 mg orally three times daily, initiated on day 1 and continued until disease progression; depot leuprolide 7...
April 1997: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/9148872/the-role-of-somatostatin-analogues-in-complete-antiandrogen-treatment-in-patients-with-prostatic-carcinoma
#13
G Vainas, V Pasaitou, G Galaktidou, K Maris, K Christodoulou, C Constantinidis, A H Kortsaris
Somatostatin analogues (SMS-A) have been found to inhibit the growth of experimental tumors, as of prostate cancer, via several mechanisms as antihormonal and direct antimitogenic actions. It was demonstrated also that several SMS-A induce greater prostatic tumor regression with more pronounced histological changes if combined with LHRH analogues or in association with complete androgen blockade (CAB). In a phase II clinical trial we administered, in addition to CAB, SMS-A octreotide in 14 patients with stage D2 (group B) prostate cancer-8 previously hormonally treated (PHT) and 6 without any previous hormone treatment (NPHT); 4 other patients, 3 NPHT and one PHT, were treated with CAB only (group A)...
March 1997: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/8717471/a-controlled-trial-of-casodex-bicalutamide-vs-flutamide-each-in-combination-with-luteinising-hormone-releasing-hormone-analogue-therapy-in-patients-with-advanced-prostate-cancer-casodex-combination-study-group
#14
RANDOMIZED CONTROLLED TRIAL
M S Soloway, P Schellhammer, R Sharifi, P Venner, A L Patterson, M Sarosdy, N Vogelzang, J Jones, G Kolvenbag
Between January 1992 and September 1993, 813 patients with stage D2 prostate cancer were enrolled in a multicentre, double-blind (for antiandrogen therapy) trial and randomised to antiandrogen therapy with Casodex (bicalutamide, 50 mg once daily) or flutamide (250 mg three times daily) and to luteinising hormone-releasing hormone (LHRH) analogue therapy with Zoladex (goserelin, 3.6 mg every 28 days) or leuprolide (7.5 mg every 28 days). Time to treatment failure was the primary efficacy endpoint. At a median follow-up time of 49 weeks, there was a significant (p = 0...
1996: European Urology
https://www.readbyqxmd.com/read/8560679/maximal-androgen-blockade-for-patients-with-metastatic-prostate-cancer-outcome-of-a-controlled-trial-of-bicalutamide-versus-flutamide-each-in-combination-with-luteinizing-hormone-releasing-hormone-analogue-therapy-casodex-combination-study-group
#15
RANDOMIZED CONTROLLED TRIAL
P Schellhammer, R Sharifi, N Block, M Soloway, P Venner, A L Patterson, M Sarosdy, N Vogelzang, J Jones, G Kolvenbag
OBJECTIVES: To review the outcome of therapy with maximal androgen blockade and compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer. METHODS: Randomized, double-blind (for antiandrogen therapy), multicenter study with a 2 x 2 factorial design. A total of 813 patients were allocated 1:1 to bicalutamide (50 mg once daily) or flutamide (250 mg three times daily), plus 2:1 to goserelin acetate (3...
January 1996: Urology
https://www.readbyqxmd.com/read/7538237/a-controlled-trial-of-bicalutamide-versus-flutamide-each-in-combination-with-luteinizing-hormone-releasing-hormone-analogue-therapy-in-patients-with-advanced-prostate-cancer-casodex-combination-study-group
#16
RANDOMIZED CONTROLLED TRIAL
P Schellhammer, R Sharifi, N Block, M Soloway, P Venner, A L Patterson, M Sarosdy, N Vogelzang, J Jones, G Kolvenbag
OBJECTIVES: To compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer. METHODS: Randomized, double-blind (for antiandrogen therapy), multicenter study with a 2 x 2 factorial design. Eight hundred thirteen patients were allocated 1:1 to bicalutamide (50 mg once daily) and flutamide (250 mg three times daily) and 2:1 to goserelin acetate (3...
May 1995: Urology
https://www.readbyqxmd.com/read/7474602/-clinicopathological-evaluation-of-etoposide-or-estramustine-phosphate-in-castrated-patients-with-advanced-prostatic-cancer
#17
RANDOMIZED CONTROLLED TRIAL
H Matsuda, K Nonomura, S Nagamori, N Shinohara, T Koyanagi, A Maru, T Matsuno, J Fujieda, S Minami, H Morita
BACKGROUND: We conducted a multicentric randomized trial to compare bilateral orchiectomy versus bilateral orchiectomy plus etoposide or estramustine phosphate as first-line therapy for advanced prostatic cancer (stage D2). METHODS: From January 1991 to December 1992 a total of 46 newly diagnosed cases (registered cases) of advanced (stage D2) prostatic cancer was randomized into 3 groups as follows; Group A: bilateral orchiectomy and 25 mg/day of etoposide every 2 weeks for 6 months...
October 1995: Nihon Hinyōkika Gakkai Zasshi. the Japanese Journal of Urology
https://www.readbyqxmd.com/read/3290578/combination-therapy-with-flutamide-and-castration-lhrh-agonist-or-orchiectomy-in-previously-untreated-patients-with-clinical-stage-d2-prostate-cancer-today-s-therapy-of-choice
#18
RANDOMIZED CONTROLLED TRIAL
F Labrie, A Dupont, L Cusan, M Giguere, N Bergeron, J P Borsanyi, Y Lacourciere, A Belanger, J Emond, G Monfette
One hundred and ninety-nine patients with clinical stage D2 prostate cancer who had not received previous endocrine therapy or chemotherapy were treated with the combination therapy using the pure antiandrogen Flutamide and the LHRH agonist [D-Trp6]LHRH ethylamide for an average of 26 months (3-59 months). The objective response to the treatment was assessed according to the criteria of the U.S. NPCP. There was a 5.7-fold increase (26.3 vs 4.6%) in the percentage of patients who achieved a complete response compared with the results obtained in five recent studies limited to removal (orchiectomy) or blockade (DES or Leuprolide) of testicular androgens...
1988: Journal of Steroid Biochemistry
https://www.readbyqxmd.com/read/3283766/combination-therapy-with-flutamide-and-castration-orchiectomy-or-lhrh-agonist-the-minimal-endocrine-therapy-in-both-untreated-and-previously-treated-patients-with-advanced-prostate-cancer
#19
COMPARATIVE STUDY
F Labrie, A Dupont, M Giguère, J P Borsanyi, Y Lacourciere, A Bélanger, R Lachance, J Emond, G Monfette
One hundred fifty-four patients with clinical stage D2 prostate cancer with no previous endocrine therapy or chemotherapy received the combination therapy with the pure antiandrogen Flutamide and the LHRH agonist [D-Trp]LHRH ethylamide for an average of 22 months (3 to 49). The objective response to the treatment was assessed according to the criteria of the US NPCP. There was a 6.3-fold increase (29.2 versus 4.6%) in the percentage of patients who achieved a complete response as compared to the results achieved in 5 recent studies limited to removal (orchiectomy) or blockade (DES or Leuprolide) of testicular androgens...
1988: Progress in Clinical and Biological Research
https://www.readbyqxmd.com/read/3100871/advantages-of-the-combination-therapy-in-previously-untreated-and-treated-patients-with-advanced-prostate-cancer
#20
RANDOMIZED CONTROLLED TRIAL
F Labrie, A Dupont, M Giguere, J P Borsanyi, A Belanger, Y Lacourciere, J Emond, G Monfette
In order to achieve a more complete blockade of androgens of both testicular and adrenal origin at the start of treatment, we have administered the pure antiandrogen Flutamide in association with orchiectomy (13 patients) or the LHRH agonist [D-Trp6]LHRH ethylamide (118 patients) to previously untreated patients with clinical stage D2 prostate cancer. The mean duration of treatment was 491 days (102-1208 days). The response was assessed according to the criteria of the U.S. National Prostatic Cancer Project...
November 1986: Journal of Steroid Biochemistry
keyword
keyword
82407
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"